Twin SUBLIVAC® Grasses Clinical Efficacy Study

NCT00422149 Phase 3 COMPLETED

To show that treatment with SUBLIVAC® Grasses is clinically effective by means of reduction in allergic symptoms and/or use of allergic symptomatic medication in subjects suffering from IgE mediated allergic complaints triggered by grass pollen.

Details

Lead sponsor	HAL Allergy
Phase	Phase 3
Status	COMPLETED
Enrolment	350
Start date	2006-09
Completion	2007-10

Conditions

• Rhinitis, Allergic, Seasonal
• Conjunctivitis, Allergic

Interventions

• SUBLIVAC® Grasses/Placebo treatment
• SUBLIVAC® Grasses treatment
• Placebo treatment

Primary outcomes

• Clinical index score (CIS), measured during the pollen season, in the treatment group compared to the placebo group. — June, July, August 2007

Countries

Belgium, Germany, Netherlands, Poland